Steiner et al.

SERIAL NO.:

09/449,817

FILED:

November 29, 1999

Page 14

REMARKS

Claims 1, 7, 10-27, 54-57, 59 and 60 are pending in the application. Claims 1, 7, 10-27, 54-57, 59 and 60 have been rejected. Claims 1, 7, 12, 13, 14, 15, 16, 21, 24, 54, 55, 56

and 59 have been amended. New claims 61, 62 and 63 have been added.

The amendments to the claims, specification and abstract and the incorporation of

new claims are editorial in nature and contain no new matter.

Specifically, contrary to the Examiner's allegation in the Office Action of August 20,

2003, claim 15 should not require further consideration for it's change in dependency since

the change has been to recite an oligonucleotide of claim 14, wherein the detectable marker

is a radioactive, colorimetric, luminescent, fluorescent marker or gold label, a change from

one that previously referred to the oligonucleotide of claim 13, which recited an

oligonucleotide comprising DNA or RNA, which is a radioactive, colorimetric, luminescent,

fluorescent marker or gold label. The amendment is editorial in nature, and reference to

radioactive, colorimetric, luminescent, etc. detectable markers is fully supported in the

specification at Page 31, lines 11-18, Page 55 lines 19-22.

Further, the amendment to claim 24, referring to the vector of claim 19, wherein the

regulatory element is a Rous Sarcoma virus promoter does not constitute new matter, nor

require further consideration, as it depends from claim 19, which recites a vector of claim 18,

further comprising an regulatory element linked to the nucleic acid molecule. The change in

dependency in claim 20 is similarly editorial in nature, and does not constitute new matter.

Both changes are fully supported in the Specification at Page 18, lines 7-12 and Page 21,

lines 13-15.

Claims 54-56 recite isolated nucleic acid moleculs of claim 1, wherein the nucleic

acid sequence shares at least 75, 85 or 95% identity with the nucleic acid sequence of SEQ ID

Steiner et al. 09/449,817

SERIAL NO.: FILED:

November 29, 1999

Page 15

NO: 1 does not constitute new matter, as it is fully supported in the Specification at Page 10,

lines 18-25, and Page lines 17-19.

Claim 59 recites an isolated nucleic acid molecule of claim 7, wherein the claimed

DNA is cDNA or genomic DNA. The change in dependency is editorial in nature, and is

fully supported in the specification at Page 10, lines 29-30. The change therefore should not

require any further consideration, and does not constitute new matter.

Newly added claim 62 recites an oligonucleotide of claim 12, in sense or antisense

orientation. Support for this claim can be found in the Specification at Page 25, lines 15-18

and Page 29, lines 20-21. Claim 63, which recites an oligonucleotide of at least 15

nucleotides capable of specifically hybridizing with a nucleic acid molecule encoding for a

variant, analog or mutant of the mammalian p-Hyde protein is supported therein as well, in

reference to oligonucleotides which specifically hybridize with the nucleic acids of the

invention. Nucleic acids encoding for a variant, analog or mutant of the mammalian p-Hyde

protein, as recited in claim 63, and referred to in claim 62 as described hereinabove, is

supported at Page 10, lines 11-15, Page 13, lines 22-35-Page 14, lines 1-18, and Page 17,

lines 5-28.

Thus all of the proposed amendments to the claims, and newly added claims are fully

supported in the Specification, and do not constitute any new matter, accordingly, Applicants

respectfully request entry of the Amendment.

PRIORITY

In the Office Action, the Examiner objected to the granting of the benefit of priority

to the Subject Application from United States non-Provisional Application No. 09/302,457,

filed on April 29, 1999. The Examiner alleged that the elected subject matter, namely the

identification of a human homologue of the p-Hyde gene and its product, has priority dating

back to the filing date of the instant application, alone. Applicants respectfully disagree. In

Steiner et al.

SERIAL NO.:

09/449,817 November 29, 1999

FILED: Page 16

United States non-Provisional Application No. 09/302,457, Applicants clearly show the identification of a human p-Hyde gene homologue (figures 8, 9 and 19A). Thus Applicants request that the Examiner withdraw his objection.

## DRAWINGS

In the Office Action, the Examiner noted that the drawings are considered informal. In response, Applicants hereby submit an amended set of formal drawings, in compliance with PTO form 948 attached to Paper No. 27. Accordingly, Applicants request withdrawal of the rejection.

## COMPLIANCE WITH THE SEQUENCE RULES

In the Office Action, the Examiner noted that statement that the content of the paper and CRF copies include no new matter as required by 37 C.F.R. 1.821 through 1.825 in insufficient since it notes that the sequence listing is "forwarded herewith" and does not refer to the sequence listing filed April 16, 2001. In response, Applicants hereby submit an amended statement which refers to the sequence listing filed April 16, 2001. Accordingly, Applicants request withdrawal of the rejection.

## OBJECTIONS TO THE SPECIFICATION

In the Office Action, the Examiner objected to the specification as allegedly containing confusing reference materials. Specifically the Examiner asserted that "[t]roughout the application, for example on page 25, line 25, bracketed reference such as "[74]" are found but do not correlate to the reference citations at the end of the application....also, "?" are found throughout the specification".

In response, Applicants have corrected the specification to deleted the "?" and to delete the reference numbers in brackets and deleted the confusing references list at the end of the specification on pages 96-101. Accordingly, Applicants respectively request that the Examiner withdraw the objection.

Steiner et al.

SERIAL NO.:

09/449,817

FILED:

November 29, 1999

Page 17

## CLAIM REJECTIONS - 35 U.S.C. § 112 SECOND PARAGRAPH

In the Office Action, the Examiner asserted that claims 1, 7, 10-27, 54-57, and 59-60 are rejected under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, by referring to the term "analogs".

In response, Applicants have amended claims 1, 7, 10-27, 54-57, and 59-60, removing all reference to the term "analog". It is respectfully asserted that the foregoing amendment merely addresses matters of form and does not change the literal scope of the claim in any way or result in any prosecution history estoppel. Therefore Applicants respectfully request Examiner withdraws the rejection.

In the Office Action, the Examiner rejected claim 16 under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, by referring to the term "sequence complementary to". In response, Applicants have herein amended claim 16 to refer to an isolated nucleic acid molecule having a nucleic acid sequence that is complementary to the nucleic acid sequence set forth in SEQ ID No. 1.

Both Claims 1 and 16 refer to a nucleic acid molecule. The Examiner objected to the nucleic acid molecule of claim 1 as allegedly encompassing DNA, which is double stranded and already contains a "complementary" sequence to the gene that encodes the protein. Applicants respectfully point out that as described in the specification on page 15 (lines 13-16), Applicants define a nucleic acid as comprising an RNA or DNA molecule in either single or double stranded form. Applicants claims to a complementary sequence, therefore recites complementary RNA or DNA which may be a single stranded DNA or RNA molecule with a nucleotide sequence that is complementary to the sequence as set forth in SEQ ID NO: 1. Therefore Applicants respectfully request that the Examiner reconsider and withdraw the rejection.

Steiner et al.

SERIAL NO.:

09/449,817

FILED:

November 29, 1999

Page 18

In the Office Action, the Examiner rejected claims 21-24 under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, by referring to

the abbreviations "BAC".

In response, claim 21 has been amended. It is respectfully asserted that the foregoing amendment merely addresses matters of form and does not change the literal scope of the claim in any way or result in any prosecution history estoppel. Thus Applicants respectfully request that the Examiner reconsider and withdraw the rejection.

CLAIM REJECTIONS - 35 U.S.C. § 112 FIRST PARAGRAPH

In the Office Action, the Examiner rejected claims 1, 7, 10-27, 54-56 and 59 under 35 U.S.C. § 112, first paragraph as allegedly failing to clearly define a structural limitation of the claimed nucleic acid sequences. In response, Applicants have hereby amended claims 1, 7, 10-27, 54-56 and 59 to refer to an isolated nucleic acid molecule, comprising a nucleic acid sequence encoding a mammalian p-Hyde protein, with a nucleic acid sequence as set forth in SEQ ID No. 1. Applicants submit that the amended claims are thus definite, and respectfully request that the Examiner withdraw the rejection.

CLAIM REJECTIONS - 35 U.S.C. § 101

In the Office Action, the Examiner rejected claims 1, 7, 10-27, 54-57 and 59-60 under 35 U.S.C. § 101 as allegedly lacking patentable utility. Applicants respectfully traverse the Examiner's rejection. Applicants submit that the subject matter defined by the claims, namely the isolated nucleic acid molecule set forth in SEQ ID No. 1 is functionally characterized in the subject Application. Applicants have presented evidence in the Subject Application demonstrating an ability of a protein encoded by homologues/sequences of the Subject Application to induce cell-death-susceptibility in prostate cancer cells. Although the Examiner asserted that the rat p-Hyde protein has credible utility, the Examiner stated that:

Steiner et al. 09/449,817

SERIAL NO.:

FILED:

November 29, 1999

Page 19

"The utility of the rat protein and gene cannot be translated into utility for the human protein

and gene because it is unclear that the sequences are related".

Applicants submit that differential p-Hyde Applicants respectfully disagree.

expression was evident in both rat and human prostate cancer cells, and that the sequences are

If the gene product functions were unrelated, there would be no highly homologous.

expectation for a comparable pattern of gene expression. Applicants therefore submit that

comparable function and thereby utility has been demonstrated in the subject Application.

Therefore, the claimed isolated nucleic acid molecule has a credible patentable utility.

Accordingly, Applicants respectfully request that the rejection of claims 1, 7, 10-27, 54-57

and 59-60 under 35 U.S.C. § 101 be withdrawn.

Claims Objections

The Examiner asserted that Claim 7 is objected to for having an improper Markush

group. According to the Examiner the members of a Markush group must be independent and

non-overlapping. In Claim 7, the group "c-DNA" is included in the group "DNA"; thus, the

Markush group is improper.

In response Applicants have amended Claim 7. Thus, claim 7 no longer contains an

improper Markush group, and accordingly, Applicants respectfully request withdrawal of the

rejection.

The Examiner objected to Claims 12-17 under 37 C.F.R. § 1.75 (c), as being allegedly

of improper dependent form for failing to further limit the subject matter of a previous claim.

Applicant is required to cancel the claim (s), or amend the claims (s) to place the claims(s) in

proper depended form, or rewrite the claim(s) in independent form. According to the

Examiner Claims 12-17 are drawn to complementary or antisense sequences, none of which

are encompassed by Claim 1, as amended.

Steiner et al.

SERIAL NO.:

09/449,817

FILED:

November 29, 1999

Page 20

In response Applicants have amended Claims 12-16 and cancelled claim 17. Claim

12 is an independent claim, referring to an oligonucleotide specifically hybridizing with a

nucleic acid molecule encoding a mammalian p-Hyde protein, wherein the nucleic acid

molecule has a sequence as set forth in SEQ ID No: 1, with claims 13-15 dependent

therefrom, and claim 16 is an independent claim, referring to an isolated nucleic acid

molecule having a nucleic acid sequence complementary to the sequence as set forth in SEQ

ID No: 1. It is respectfully asserted that the foregoing amendment merely addresses matters

of form and does not change the literal scope of the claims in any way or result in any

prosecution history estoppel. Thus, Applicants have rewritten the claims in proper

independent form, and accordingly, Applicants respectfully request withdrawal of the

rejection.

The Examiner asserted that Claim 14 is objected to for having allegedly an improper

format and for being inconsistent with previous claims. A period is required at the end of the

claim. Also, the claim should depend from Claim 14 and cite—wherein the detectable

marker—and not "wherein the oligonucleotide" for consistency with previous claims.

In response Applicants have amended Claim 14. Thus amended Claim 14 has a proper

format, and is now consistent with previous claims. Accordingly, Applicants respectfully

request withdrawal of the rejection.

The Examiner asserted that Claim 59 is objected to for allegedly depending from a

non-elected claim, Claim 53.

In response Applicants have amended Claim 59 to depend from claim 7. Thus Claim

59 properly depends from an elected claim. Accordingly, Applicants respectfully request

withdrawal of the rejection.

REJECTIONS ON 35 U.S.C. § 102

Steiner et al.

SERIAL NO.:

09/449,817

FILED:

November 29, 1999

Page 21

In the Office Action, the Examiner rejected claims 1, 7, 12, 13, 16 and 17 under 35 U.S.C. § 102(b), as allegedly being anticipated by Hillier et al. In response, Applicants respectfully traverse this rejection in view of the remarks that follow.

Claim 1 has been herein amended to recite an isolated nucleic acid molecule encoding for a mammalian p-Hyde protein comprising a nucleic acid sequence as set forth in SEQ ID No. 1. The Examiner has asserted that Hillier et al. disclose "a human mRNA EST sequence that matches 155 nucleotides of Applicants' SEQ ID No: 1", yet does not comprise the sequence in its entirety, and therefore Hillier et al., does not anticipate claim 1.

The nucleotide sequence disclosed by Hillier et al., is not a p-Hyde coding sequence as set forth in SEQ ID No. 1. In order for Hillier et al to be anticipatory of claim 12, the Hillier nucleotide sequence must disclose the p-Hyde coding sequence. Hillier et al., do not disclose oligonucleotides per se, and do not disclose a sequence encoding p-Hyde, as the sequence disclosed by Hillier et al does not in fact code for a functional protein. Thus Applicants submit that Hillier et al., does not anticipate claims 1 or 12.

Claim 16 has been amended to recite an isolated nucleic acid molecule comprising a nucleic acid sequence complementary to that set forth in SEQ ID No. 1. As in claim 1, Hillier et al do not disclose the full p-Hyde coding sequence, and hence does not anticipate claim 16.

Claim 17 has been cancelled.

Applicants respectfully assert that amended independent claims 1, and dependent claim 7, 12 and dependent claim 13, and 16, are allowable. Accordingly, Applicants respectfully request that the Examiner withdraw the rejections to claims 1, 7, 12, 13 and 16.

Further, in the Office Action, the Examiner rejected claims 1, 7, 10-21, 25-27, 54-56 and 59 under 35 U.S.C. § 102(b), as being anticipated by Talerman et al. In response, Applicants respectfully traverse this rejection in view of the remarks that follow.

Steiner et al.

SERIAL NO.:

09/449,817

FILED:

November 29, 1999

Page 22

The Examiner asserted that Talerman et al. disclose "a DNA sequence that is 72% similar and 39% identical to Applicants' SEQ ID No: 1". Claim 1 has been herein amended to recite an isolated nucleic acid molecule encoding for a mammalian p-Hyde protein having a nucleic acid sequence as set forth in SEQ ID No. 1. The Examiner has asserted that Talerman et al. does not comprise the complete sequence as set forth in SEQ ID No. 1. The nucleotide sequence disclosed by Talerman et al., does not encode for p-Hyde, and, moreover, is not functionally comparable. Talerman et al discloses TSAP sequences, which are known to function in upregulation of apoptosis in a p53-dependent manner, following p53 In the instant invention, however, p-Hyde functions through a different mechanism, acting as both a tumor suppressor, and as an apoptotic inducer, via its ability to impair DNA repair enzyme function. Talerman et al do not disclose a molecule that functions to impair DNA repair enzyme function. Thus functionally, and structurally, TSAP as disclosed by Talerman et al., differs from the instant invention, and therefore does not anticipate Claim 1, or dependent claims thereof. Claims 7, 10, 11, 18-21, 25-27 and 59 directly depend from claim 1, and therefore Applicants maintain is not anticipated by Tallerman et al., accordingly.

Claim 12 has been amended to recite an oligonucleotide of at least 15 bases capable of specifically hybridizing with a nucleic acid molecule encoding a mammalian p-Hyde protein comprising a sequence as set forth in SEQ ID No. 1. In order for Talerman et al to be anticipatory of claim 12, the nucleotide sequence disclosed by Talerman et al. must teach the nucleotide sequences from which an oligonucleotide specifically hybridizing with a nucleic acid sequence encoding for p-Hyde protein are designed. Talerman et al., do not teach a sequence encoding p-Hyde, thus Applicants submit that Talerman et al., does not anticipate claim 12. Claims 13-15 directly depend from claim 12, and therefore Applicants maintain is not anticipated by Talerman, et al., accordingly.

Claim 16 has been amended to recite an isolated nucleic acid molecule comprising a nucleic acid sequence complementary to that set forth in SEQ ID No. 1. As in claim 1,

Steiner et al.

SERIAL NO.

09/449,817

FILED:

November 29, 1999

Page 23

Talerman et al., do not disclose a sequence encoding p-Hyde, and hence do not anticipate

claim 16. Accordingly, Applicants respectfully assert that amended independent claim 16 is

allowable.

The Examiner has stated that Tallerman et al. anticipates claims 54-56. Claims 54-56

recite a nucleic acid molecule of claim 1, with the further restriction that the nucleic acid

sequence share at least 75 %, at least 85% or at least 95% identity with p-Hyde. The

Examiner has in fact indicated that the greatest degree of identity is 39%, and only a 72%

similarity. Similarity implies functional comparability, which Applicants submit is absent in

Tallerman et al., further, Applicants least degree of identity claimed is 75 %, well above the

values for both sequence identity and similarity, as claimed by Tallerman et al.

Therefore, Applicants respectfully assert that claims 1, 7, 10-21, 25-27, 54-56 and 59

are allowable. Accordingly, Applicants respectfully request that the Examiner withdraw the

objections to the claims.

In view of the foregoing amendments and remarks, the pending claims are deemed to

be allowable. Their favorable reconsideration and allowance is respectfully requested.

Should the Examiner have any question or comment as to the form, content or entry

of this Amendment, the Examiner is requested to contact the undersigned at the telephone

number below. Similarly, if there are any further issues yet to be resolved to advance the

prosecution of this application to issue, the Examiner is requested to telephone the

undersigned counsel.

Please charge any fees associated with this paper to deposit account No. 05-0649.

APPLICANT(S): Steiner et al. SERIAL NO.: 09/449,817

FILED:

November 29, 1999

Page 24

Respectfully, submitted,

Mark S. Cohen

Attorney for Applicant(s) Registration No. 42,425

Dated: April 14, 2004

Eitan, Pearl, Latzer & Cohen Zedek, LLP

10 Rockefeller Plaza, Suite 1001 New York, NY 10020 Telephone: (212) 632-3494

Fax: (212) 632-3489